7HC
7HC is an Italian cloud-based software company that provides in silico drug discovery and pharmacology prediction tools — drug-target affinity, ADMET, and patient health trajectory — to pharmaceutical firms, red-biotech companies, clinical practitioners, and precision nutrition users, primarily through EU-funded research consortium participation.
- Company typePrivate
- Founded2021
- HeadquartersRoma, Italy
- Headcount1–10
- GTM typeB2B
- OfferingSoftware
What 7HC does
7HC S.r.l. (7 Health Computing) is an Italian computational biology company founded in 2021 and headquartered in Rome. The company has built a cloud-based software platform for in silico prediction of pharmacological efficacy, allowing pharmaceutical and red-biotech users to estimate drug-receptor affinity, pharmacokinetics, and small-molecule physiology (water solubility, logP, logD, Kd, IC50, blood-brain barrier penetration, drug likeness, toxicity) directly from SMILES molecular strings and protein amino acid sequences. The platform runs on Amazon EC2 and S3, integrates with the Protein Data Bank, and uses GROMACS for pharmaco-receptor interaction kinetics calculations; it automatically selects the best ML model per query type. The platform is delivered as a web-based SaaS solution targeting pharmaceutical firms, red-biotech companies, clinical practitioners (via an explainable-ML Cardiovascular Risk Predictor), and precision nutrition/agriculture users through specialized modules.
The company's product portfolio includes the core 7HC Computational Platform, a Drug Property Prediction Module, a Clinical Decision Support module, the COVID-19 Piacenza Score (published 2021 in JMIR), a Precision Nutrition and Agriculture module, and emerging AI-based Virtual Cell Models / digital twins for neurodegenerative disorders. Business operations are dominated by EU-funded research consortium participation rather than disclosed commercial SaaS sales: 7HC is a partner in at least nine EU programmes (Horizon MSCA-ITN/SE, PNRR Partenariato Esteso FAIR/RETURN, Eurostars), including the €2.3M NEUROSPARK project (announced February 2026) targeting Spinocerebellar Ataxia Type 3 with InVirtuoLabs, INSYBIO, and oloBion. The leadership team comprises a PhD CEO with 20+ years in biomedical engineering and a CTO with prior database engineering experience at Expedia, Booking.com, LastMinute, and Telefonica Group; the organization has 1–10 employees and no disclosed external venture funding.
7HC firmographics
Firmographics- Name
- 7HC
- Legal name
- 7HC S.r.l.
- Website
- https://7hc.tech
- Company type
- Private
- Founded year
- 2021
- Operating status
- Operating
- Headcount range
- 1–10 employees
- Short description
- 7HC is an Italian cloud-based software company that provides in silico drug discovery and pharmacology prediction tools — drug-target affinity, ADMET, and patient health trajectory — to pharmaceutical firms, red-biotech companies, clinical practitioners, and precision nutrition users, primarily through EU-funded research consortium participation.
- Ownership category
- akta.pro rank
7HC industry classification
Industry- Product category
- Computational Drug Discovery Software
- NAICS
- Research and Development in Biotechnology (except Nanobiotechnology) (541714), Scientific Research and Development Services (5417)
- SIC
- Laboratory Analytical Instruments (3826)
- akta.pro primary industry
- AI/ML Platforms for Drug Discovery & Experiment Optimization (HLAGAJAO)
Keywords
Where 7HC is headquartered
LocationHeadquarters
- HQ city
- Roma
- HQ country
- Italy
- HQ region
- Europe
Offices1 record
Markets served
7HC business model
Business model- GTM type
- B2B
- Offering type
- Software
- Cost components
- Technology or R&D, Personnel, Infrastructure, Operations
Revenue model
- SaaS Platform Access: 7HC provides its computational platform as a cloud-based service on demand. The platform manages IT resources for data storage, processing and transmission according to user requests. Pharmaceutical companies and biotech firms access the service through a web interface without requiring expensive hardware resources.
- Research Collaboration and Grants: 7HC participates in EU-funded research projects (Horizon Europe, MSCA, PNRR) as a consortium partner. These collaborative research projects contribute to technology development and operational funding.
Go-to-market motion1 record
Distribution channels1 record
Marketing channels3 records
7HC product offering
Product offeringCore offering
7HC provides a cloud-based computational platform for in silico prediction of pharmacological efficacy, targeting pharmaceutical industries and red-biotech companies. The platform processes molecular inputs (SMILES strings and protein sequences) through machine learning algorithms to estimate drug-receptor affinity, pharmacokinetics, water solubility, logP/logD, Kd/IC50, blood-brain barrier penetration, and toxicity. Delivered as a web-based SaaS, it supports drug design and optimization, clinical decision support (cardiovascular risk), and precision nutrition applications.
Product overview
7HC is a unified computational platform combining Internet of Things and Cloud Computing technologies for healthcare applications. The core 7HC Computational Platform serves as an integrated software platform for in silico drug discovery, complemented by specialized modules including the Cardiovascular Risk Predictor for clinical decision support, the Drug Property Prediction Module for pharmaceutical research, and the Precision Nutrition Platform for agriculture and nutrition applications. The platform processes molecular inputs (SMILES strings and protein sequences) through machine learning algorithms to predict drug efficacy, pharmacokinetics, and patient health trajectories, accessible via web-based interface.
Differentiator
Problem solved
Functional benefit
Quantifiable outcome
- Reduces the number of experiments required in the first phase of drug development
- +2 more outcomes
Companies that use 7HC
Customer profileSegments4 records
Ideal customer profiles3 records
7HC technology and API
TechnologyAPI detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability12 records
Feature5 records
7HC partnerships and signals
Strategic signalPartnerships
14 partnerships are on record, tiered core, major and minor.
- InVirtuoLabscoreInVirtuoLabs, a biotech startup, leads the €2.3 million Eurostars-funded NEUROSPARK project. 7HC participates as a partner along with INSYBIO (Greece) and oloBion (Spain). The 36-month project aims to identify and validate 3-5 lead small molecules for Spinocerebellar Ataxia Type 3 (SCA3) using AI-based Virtual Cell Models as digital twins of diseased cells.
- INSYBIOcoreGreek biotech company partner in the NEUROSPARK Eurostars grant project for SCA3 drug discovery.
- oloBioncoreSpanish biotech company partner in the NEUROSPARK Eurostars grant project for SCA3 drug discovery.
- Cellex s.r.lmajorCellex s.r.l coordinates the 3D-creator project for developing an automated platform for bioengineered tissue culture (bone and esophageal tissues). 7HC participates along with Fondazione Edoardo Amaldi and CNR Institute of Translational Pharmacology.
- Fondazione Edoardo Amaldi (FEA)majorThe E. Amaldi Foundation is a partner in the 3D-creator project for automated bioengineered tissue culture platform development.
- CNR Institute of Translational Pharmacology (IFT)majorThe Institute of Translational Pharmacology of the National Research Council (CNR) is a partner in the 3D-creator project for automated bioengineered tissue culture platform development.
- PARENT Consortium (Horizon MSCA-ITN)majorPARENT is a Horizon-MSCA-ITN-2020 project (Grant Agreement N° 956394) focused on early diagnosis of newborn motor/cognitive impairments. 7HC participates in this multidisciplinary and inter-sectorial network of European research groups, industry partners, pediatric hospitals and associations, training 15 Early Stage Researchers.
- OSTEONET Consortium (Horizon MSCA-SE)majorOSTEONET is a Horizon-MSCA-SE-2021 project (Grant Agreement N° 101086329) developing in vitro 3D cell models of healthy and osteopathological ageing bone tissue for implantation and drug testing.
- FAIR Program (Future Artificial Intelligence Research)majorFAIR is a PNNR Partenariato Esteso (Extended Partnership) focused on Human-Centered AI. The TECHNET project, in which 7HC participates, aligns with FAIR objectives (Spoke 1, themes TP3 and TP6) for automated emotion analysis during Narrative Exposure Therapy.
- RETURN Consortium (PNRR)majorRETURN is a PNRR Partenariato Esteso focused on Multi-Risk Science for resilient communities under a changing climate. 7HC participates in Spoke 5 (Urban Settlements) through the URBAN SHIELD project for monitoring urban transformations and environmental risk analysis.
- SOSVITI Consortium (Horizon MSCA-SE)minorSOSVITI is a Horizon-MSCA-SE-2023 project (Grant Agreement N° 101182765) developing an advanced framework for sustainable soil management in viticulture using AI, remote sensing, and decision-support tools.
- Galatea Consortium (Horizon MSCA-SE)minorGalatea is a Horizon-MSCA-SE-2023 project (Grant Agreement N° 101183057) developing a digital twin of human milk for personalized infant nutrition, particularly for prematurely born infants.
- SMARTOLIVE Consortium (Horizon MSCA-SE)minorSMARTOLIVE is a Horizon-MSCA-SE-2024 project (Grant Agreement N° 101236434) developing a Decision Support System for modern olive farming, using IoT and AI for supply chain management.
- WATERDEAL Consortium (Horizon MSCA-SE)minorWATERDEAL is a Horizon-MSCA-SE-2025 project (Grant Agreement N° 101299840) addressing water scarcity through IoT, AI-driven analytics, and cloud-edge computing for smart Water Supply Systems.
Scale indicators3 records
Recent moves6 records
Expansion highlights6 records
7HC competitors and assessment
Company assessmentEmerging players
- Owkin: Owkin applies AI to biomedical research and clinical outcomes, with a focus on explainable ML for clinical decision support. Overlaps with 7HC's Cardiovascular Risk Predictor and explainable-ML clinical decision support offering.
- Iambic Therapeutics: Iambic Therapeutics (formerly Entasis Therapeutics's AI arm) uses AI/ML for small-molecule design and prediction of clinical PK/PD outcomes. Comparable emerging player with similar focus on AI-native molecular property prediction and therapy optimisation.
Direct peers
- Exscientia: Exscientia is an AI-driven pharmatech combining ML with automated chemistry to design and develop novel small molecules. Comparable to 7HC as both companies pursue AI-first drug design with pharma partnerships and proprietary pipelines.
- XtalPi: XtalPi combines AI, quantum physics, and cloud computing to predict small-molecule properties and crystal forms for pharma R&D. Direct overlap with 7HC's cloud-based molecular property and binding prediction workflow.
- Atomwise: Atomwise provides AI-driven small-molecule discovery using deep learning on protein-ligand binding (AtomNet). It directly competes with 7HC on automated molecular property prediction and virtual screening for pharma and biotech customers.
- BenevolentAI: BenevolentAI applies AI/ML to drug discovery and clinical development, combining biomedical knowledge graphs with ML to identify targets and predict efficacy. Overlaps with 7HC's drug-target affinity prediction and patient health trajectory modelling.
- Insilico Medicine: Insilico Medicine is an AI-driven drug discovery company using generative chemistry, target identification, and clinical prediction. It is a direct peer to 7HC's computational pharma platform, especially around ML-based drug property and PK/PD prediction.
- InVirtuoLabs: InVirtuoLabs is a biotech that builds AI-based Virtual Cell Models / digital twins for lead molecule identification and validation. It is a consortium partner of 7HC in NEUROSPARK, but also a direct peer because both companies apply AI virtual cell/digital-twin methodologies to small-molecule discovery in rare disease.
Broad incumbents
- Recursion Pharmaceuticals: Recursion combines high-throughput biology with AI/ML for drug discovery, with a deep pipeline in rare diseases and phenomics. It is a broad incumbent operating at scale in AI-driven pharma R&D — the same category where 7HC competes.
- Schrödinger, Inc. Schrödinger operates a physics-informed computational platform for molecular simulation and drug discovery (LiveDesign). It is a broad incumbent covering the same AI/ML-driven molecular property and binding prediction use cases that 7HC's core platform addresses, but at much larger scale and with an established pharma customer base.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat5 records
Key risks6 records
Key highlights6 records
Customer concentration
7HC social profiles
Digital presence7HC financial estimates
Financial estimateRevenue estimate
Valuation estimate
7HC leadership team
Management profileNumber of profiles
Profiles3 records
7HC funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
7HC M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about 7HC
What does 7HC do?
7HC provides a cloud-based computational platform for in silico prediction of pharmacological efficacy, targeting pharmaceutical industries and red-biotech companies. The platform processes molecular inputs (SMILES strings and protein sequences) through machine learning algorithms to estimate drug-receptor affinity, pharmacokinetics, water solubility, logP/logD, Kd/IC50, blood-brain barrier penetration, and toxicity. Delivered as a web-based SaaS, it supports drug design and optimization, clinical decision support (cardiovascular risk), and precision nutrition applications.
Is 7HC a public or private company?
7HC is a private company. It is classified as founder individual operated bootstrapped and is currently operating.
When was 7HC founded?
7HC was founded in 2021. It employs 1 to 10 people.
Where is 7HC based?
7HC is headquartered in Roma, Italy, in the Europe region.
How does 7HC make money?
Two revenue lines are on record. SaaS Platform Access are the primary driver. The others are research Collaboration and Grants.
Who are 7HC's main competitors?
Emerging players on record are Owkin and Iambic Therapeutics. Direct peers are Exscientia, XtalPi, Atomwise, BenevolentAI, Insilico Medicine and InVirtuoLabs. Broad incumbents are Recursion Pharmaceuticals and Schrödinger, Inc..
Does 7HC have an API?
No public API is recorded for 7HC.
What industry is 7HC in?
7HC's product category is Computational Drug Discovery Software. Its primary akta.pro industry code is HLAGAJAO, AI/ML Platforms for Drug Discovery & Experiment Optimization. Its NAICS code is 541714 and its SIC code is 3826.